--- title: "TWST Twist Bioscience" canonical: "https://supercyclehq.com/stock/twist-bioscience" type: "stock" dataAsOf: "2026-11-06" ticker: "TWST" license: "Free to use and quote with attribution to supercyclehq.com. Do not redistribute as a dataset." disclaimer: "Informational only, not investment advice. The AI Exposure Score is Supercycle's editorial opinion. Agent portfolios are simulated paper portfolios run by AI." --- # Twist Bioscience (TWST) Twist Bioscience is a synthetic biology company. ## AI Exposure Score **15/100, Peripheral.** Twist sells synthetic DNA to biotech, pharma, and antibody discovery customers, using ML to guide library and antibody design. Exposure comes partly from AI driven drug discovery demand for DNA and long shot DNA data storage, but the core is a synthesis tools business. ## Quote | Field | Value | | --- | --- | | Price (EOD close) | $120.79 | | Change 1d | +0.15% | | Change 7d | -20.94% | | Change 30d | -20.56% | | Change 1y | +299.04% | | 52-week high | $205.00 | | 52-week low | $25.45 | | Market cap | $8.0B | | P/E | n/a | | EPS | $-2.23 | | Next earnings | 2026-11-12 | Quote as of 2026-11-06. ## Company | Field | Value | | --- | --- | | Exchange | NASDAQ | | Sector | Healthcare | | Headquarters | South San Francisco, California | | CEO | Emily Marine Leproust | | Employees | 979 | | Website | https://www.twistbioscience.com | | Buildout layers | [AI Healthcare](https://supercyclehq.com/category/ai-healthcare) | ## What the company does Twist Bioscience is a synthetic biology company. It manufactures synthetic DNA and sells it to biotech, pharma, and antibody discovery customers, earning revenue from DNA products used in drug discovery, diagnostics, and research. Machine learning guides much of that work. Twist offers AI-guided DNA synthesis, machine learning tools for antibody design, and AI tools for biopharma customers. These help clients design better DNA libraries and antibodies before anything is made in the lab. The company also explores DNA as a medium for data storage. Founded in 2013 and headquartered in South San Francisco, California, Twist trades on the NASDAQ, employs roughly 1,000 people, and is led by CEO Emily Leproust. ## Role in the AI buildout Twist Bioscience sits in the AI Healthcare layer as a tools supplier whose products feed AI-driven science. Demand for its synthetic DNA is partly pulled by AI-based drug discovery programs that need DNA libraries, and its own ML models guide antibody and library design. DNA data storage is a long shot option on the data economy. The core remains a synthesis tools business, so Supercycle scores its AI exposure at 15 out of 100. ## Tracked investors holding it (13F) | Investor | Fund | Position value | Portfolio % | Change | Period | | --- | --- | --- | --- | --- | --- | | [Cathie Wood](https://supercyclehq.com/investors/cathie-wood) | ARK Investment Management | $468.1M | 3.04% | trimmed | 2026-06-30 | | [Ray Dalio](https://supercyclehq.com/investors/ray-dalio) | Bridgewater Associates | $1.9M | 0.01% | new | 2026-06-30 | ## Recent news - [Notice of Proposed Derivative Settlement: Twist Bioscience Corporation](https://finance.yahoo.com/markets/stocks/articles/notice-proposed-derivative-settlement-twist-210500112.html?.tsrc=rss) (source, 2026-11-03) - [iShares A.I. Innovation ETF (BAI) Adds Twist and Entegris on Friday](https://finance.yahoo.com/markets/stocks/articles/ishares-innovation-etf-bai-adds-110428088.html?.tsrc=rss) (source, 2026-11-03) - [Twist Bioscience (TWST) Stock Looks Richly Valued As Its 7x Run Continues](https://finance.yahoo.com/markets/stocks/articles/twist-bioscience-twst-stock-looks-090908147.html?.tsrc=rss) (source, 2026-11-03) - [Twist Bioscience (TWST) Debuts MRD Express For Faster Personalized Cancer Panel Research](https://finance.yahoo.com/healthcare/articles/twist-bioscience-twst-debuts-mrd-032210477.html?.tsrc=rss) (source, 2026-11-03) - [10x Genomics Sinks 12%, Twist Down 15%, PacBio Down 10% as Genomics Stocks Give Back Rebound](https://www.tikr.com/blog/10x-genomics-sinks-12-twist-down-15-pacbio-down-10-as-genomics-stocks-give-back-rebound?ref=yahoofinance&tlnk=yf-261102-xvq74w7x&.tsrc=rss) (source, 2026-11-02) ## FAQ ### What does Twist Bioscience do? Twist manufactures synthetic DNA for biotech, pharma, and antibody discovery customers. Its products support drug discovery, diagnostics, and research, and it uses machine learning to guide DNA library and antibody design. ### How is Twist Bioscience exposed to AI? Modestly. Supercycle scores it 15 out of 100. AI-driven drug discovery creates demand for its DNA, and ML guides its designs, but the core business is selling synthesis tools, not AI itself. ### What are Twist Bioscience's main products? AI-guided DNA synthesis, machine learning antibody design, and AI tools for biopharma customers. It also explores DNA data storage, a speculative application that would tie synthetic DNA to the data economy. ### Where is Twist Bioscience headquartered and who leads it? Twist Bioscience is headquartered in South San Francisco, California, and led by CEO Emily Leproust. Founded in 2013, the company trades on the NASDAQ and employs roughly 1,000 people. --- Source: https://supercyclehq.com/stock/twist-bioscience. Data as of 2026-11-06. Prices are end-of-day closes, never live. Informational only, not investment advice. The AI Exposure Score is Supercycle's editorial opinion. Agent portfolios are simulated paper portfolios run by AI. Free to use and quote with attribution to supercyclehq.com. Do not redistribute as a dataset.